

Overexpression of cyclin E messenger ribonucleic acid in nasopharyngeal carcinoma correlates with poor prognosis

M-T KO, C-Y SU, S-C HUANG*, C-H CHEN, C-F HWANG

Abstract

Aims: S-phase kinase-associated protein 2 is required for the degradation of p27 protein, which is a negative regulator of cyclin E/cyclin-dependent kinase 2 complex. The present study examined the expression of cyclin E, S-phase kinase-associated protein 2 and p27 protein in nasopharyngeal carcinoma.

Methods: Tissue from 35 cases of nasopharyngeal carcinoma and 10 normal nasopharyngeal tissue samples underwent reverse polymerase chain reaction to detect messenger ribonucleic acid. Immunohistochemical analysis was performed on 29 nasopharyngeal tissue samples in order to detect protein expression.

Results: Messenger ribonucleic acid expression in the nasopharyngeal carcinoma tissue samples analysed indicated a 1.75-fold change in the amount of S-phase kinase-associated protein 2, a 0.34-fold change in the amount of cyclin E and a 0.31-fold change in the amount of p27 protein, compared with positive controls. High levels of cyclin E significantly correlated with late-stage nasopharyngeal carcinoma ($p = 0.009$) and a poor overall survival ($p = 0.010$). Immunohistochemical analysis indicated positive expression of S-phase kinase-associated protein 2 in 16/29 nasopharyngeal tissue samples (55 per cent), of cyclin E in 13/29 samples (45 per cent) and of p27 protein in 17/29 (59 per cent) samples.

Conclusions: Overexpression of cyclin E messenger ribonucleic acid showed an adverse prognostic significance, correlating with an advanced stage of nasopharyngeal carcinoma and a low overall survival rate.

Key words: Nasopharyngeal Neoplasms; Cyclin E; Skp2 protein; p27 Kipl protein

Introduction

It is now believed that dysregulation of the cell cycle of proliferation contributes to the development of many malignant tumours. The p27 protein, a cyclin-dependent kinase inhibitor, play an important role in blocking the normal cell cycle from gap1 G1 to synthesis S by negatively regulating the cyclin E/cyclin-dependent kinase 2 and cyclin A/cyclin-dependent kinase 2 complexes, and thereby inducing cell growth arrest.¹ Degradation of the p27 protein during the cellular proliferation process has been reported, both *in vitro* and *in vivo*, through its phosphorylation on threonine 187, mediated by S-phase kinase-associated protein 2 (a human F-box protein which is necessary for deoxyribonucleic acid (DNA) replication)² within the post-translational ubiquitin-proteasome pathway.^{1,3,4} Thus, S-phase kinase-associated protein 2 is an important protein in controlling the p27 degradation process. Increased expression of S-phase kinase-associated protein 2 and cyclin E may accelerate cell proliferation.

High levels of both these proteins have been reported to correlate with the malignant status of many tumours.^{5–9}

Nasopharyngeal carcinoma (NPC), a malignant tumour of the nasopharyngeal epithelium, is classified by the World Health Organization into three types.^{10,11} World Health Organization types II and III NPCs are highly prevalent in endemic areas such as South-east Asia, northern and eastern Africa, and some North American indigenous populations. These NPCs are strongly associated with Epstein-Barr virus, although some genetic and environmental factors have been documented as playing a role in their development.

No previous reports have involved the role of cyclin E in NPC. In the present study, we assessed the messenger ribonucleic acid (mRNA) and protein expressions of S-phase kinase-associated protein 2, cyclin E and p27 protein in NPC patients, and we analysed data to determine any clinicopathological correlations.

From the Departments of Otolaryngology and *Pathology, Chang Gung Memorial Hospital – Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Accepted for publication: 13 November 2008. First published online 11 March 2009.

Materials and methods

Subjects and specimens

Fresh nasopharyngeal biopsy specimens were obtained from 45 patients presenting with symptoms or signs possibly indicative of NPC. All patients underwent nasopharyngeal biopsy during their initial visit. The study population comprised 35 NPC patients (27 men and eight women) with a mean age of 50.6 years (range, 17–84 years). The non-malignant group comprised 10 patients (seven men and three women; mean age, 35.7 years; age range, 19–53 years) with a nasopharyngeal mass that was later confirmed to be negative for NPC.

Fresh tissue blocks were cut into two pieces: one was used for histopathological examination and the other was stored at -80°C for later use.

Our protocol was reviewed and approved by the local hospital institutional review board.

Ribonucleic acid extraction and reverse transcription polymerase chain reaction

For RNA preparation, tissue samples were cut into small pieces and RNA extracted using Tri-Zol reagent (Life Technologies, Gaithersburg, Maryland, USA). A total of 2 μg of RNA from each sample was reverse-transcribed into copy deoxyribonucleic acid, (cDNA) then amplified by polymerase chain reaction (Promega, Madison, WI, USA) using the following primers: for S-phase kinase-associated protein 2 primer, 5'-GCT GCT AAA GGT CTC TGG TGT- 3' (forward) and 5'-AGG CTT AGA TTC TGC AAC TTG-3' (reverse); for p27, 5'-AGG ATG TCA GCG GGA GCC GC-3' (forward) and 5'-CTT CTT GGG CGT CTG CTC CA-3' (reverse); and for cyclin E, 5'-AAT CGA CAG GAC GGC GAG GGA C-3' (forward) and 5'-GGC AGT CAA CAT CCA GGA CAC A-3' (reverse) (where G = guanine, C = cytosine, T = thymine and A = adenine). The level of mRNA was assessed by a densitometer (Kodak Digital Science 1D software program, Rochester, New York, USA).¹² All gels containing polymerase chain reaction amplicons were scanned with the Kodak Image System and electronically evaluated with the Kodak Digital Science 1D software, which enabled comparison of the grey scales of the scanned amplicons in relation to the positive controls.¹³ Relative quantities of mRNA were determined. The same nasopharyngeal carcinoma tissues were used as external positive controls in all polymerase chain reaction examinations. A glyceraldehyde-3-phosphate dehydrogenase copy DNA probe was used as an internal positive control.

Immunohistochemistry

Archival, pretreatment tumour tissue was obtained from 29 patients with NPC. Primary antibodies for S-phase kinase-associated protein 2 (Santa Cruz Biotechnology, Santa Cruz, California, USA), cyclin E (Santa Cruz Biotechnology, Santa Cruz, California, USA) and p27 (Dako, Glostrup, Denmark) were diluted 1:50 in phosphate-buffered saline. The sections were deparaffinised and

incubated overnight at 37°C , and then treated with 3 per cent hydrogen peroxide to deprive the endogenous peroxidase activity and microwaved in 10 mM citrate buffer (pH 6.0) to unmask the epitopes. After antigen retrieval, the sections were incubated with diluted primary antibodies overnight and then washed with phosphate-buffered saline. Horseradish peroxidase/Fab polymer conjugate (PicTure™-Plus kit; Zymed, San Francisco, California, USA) was then applied to the sections. After extensive washing, the sections were incubated with peroxidase substrate diaminobenzidine. Thereafter, the sections were counterstained with Gill's haematoxylin and mounted with mounting medium.

All the sections were interpreted by a pathologist (SCH) blinded to the clinical data. Between 15 and 20 high-power fields were viewed. The stain strength was graded as 0+, 1+, 2+ or 3+, and the expression percentage as weak (<5 per cent), moderate (5–50 per cent) or intensely positive (>50 per cent) depending on the number of positive tumour cells.

Statistical analysis

Data were analysed using the Statistical Package for the Social Sciences software (version 13.0 for Windows, Apache, Chicago, Illinois, USA). The analysis of variance test was used to evaluate the data for S-phase kinase-associated protein 2, cyclin E and p27 protein regarding comparisons between NPC and normal tissue, and also to evaluate the other parameters in each group. Survival rates were calculated by the Kaplan–Meier method using a log-rank test. A *p* value less than 0.05 was considered statistically significant.

Results

Tissue from 35 NPC cases and 10 normal subjects underwent reverse transcriptase polymerase chain reaction. All NPC patients underwent local head and neck examinations before treatment, along with staging examinations (including whole body bone scans, abdominal ultrasonography, computed tomography and magnetic resonance imaging) (Table I). The tumour–node–metastasis (TNM) staging system (International Union Against Cancer (UICC), 1997) was used for clinical staging.¹⁴ Three patients who did not complete the staging examinations or were lost to follow up were excluded from the prognostic factor analysis. The reverse transcriptase polymerase chain reaction analysis of tissue from 35 NPC patients demonstrated a 1.75-fold amount of S-phase kinase-associated protein 2 mRNA expression, a 0.34-fold amount of cyclin E mRNA expression and a 0.31-fold amount of p27 mRNA expression, compared with the positive controls (Figure 1). Compared with normal tissue, the mRNA expression levels were altered 0.85-, 0.39- and 0.73-fold, respectively. A statistically significant difference was seen for S-phase kinase-associated protein 2 and p27 protein, comparing NPC and normal nasopharyngeal tissue ($p = 0.002$ and $p = 0.002$, respectively).

Thirty-two patients were followed up for between 42 and 105 months (mean = 56.6 months). To

TABLE I
DEMOGRAPHIC DATA FOR NPC PATIENTS

Characteristic	n	%
Age (y)		
≥50	16	45.7
<50	19	54.3
Sex		
Male	27	77.1
Female	8	22.9
WHO tumour type		
I	2	5.7
II	20	57.1
III	13	37.2
Tumour stage*		
T ₁	9	28.1
T ₂	13	40.6
T ₃	2	6.3
T ₄	8	25.0
Nodal stage*		
N ₀	7	21.9
N ₁	9	28.1
N ₂	10	31.2
N ₃	6	18.8
TNM staging*		
I	3	9.4
II	11	34.3
III	6	18.8
IV	12	37.5
Survival [†]		
Alive	23	71.9
Death	9	28.1

*Staging was incomplete for three patients. [†]Three patients were lost to follow up. NPC = nasopharyngeal carcinoma; y = years; WHO = World Health Organization; TNM = tumour–node–metastasis

facilitate analysis of prognostic factors, stage I and II tumours were grouped together as early stage and stages III and IV as late stage. At the time of writing, all early-stage cases were alive, and their prognoses were significantly better than those of the late-stage cases ($p = 0.002$, by Kaplan–Meier method using log-rank test, not shown). Cyclin E showed a strong association with late-stage NPC ($p = 0.009$) and poor survival ($p = 0.023$) (Table II). Results for the three proteins analysed




FIG. 1

Reverse transcription polymerase chain reaction analysis for cyclin E, S-phase kinase-associated protein 2 (Skp2) and p27 protein in nasopharyngeal carcinoma tissue. GAPDH was used as an internal positive control to normalize the amount of RNA. Lanes 1–9 nasopharyngeal carcinoma; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; P = external positive control.

TABLE II
CORRELATION OF SKP2, CYCLIN E AND P27 EXPRESSION WITH CLINICOPATHOLOGICAL STATUS

Characteristic	Pts (n)	Correlation		
		Skp2	Cyclin E	p27
Age (y)				
≥50	16	2.005	0.316	0.289
<50	19	1.541	0.357	0.326
<i>p</i>		NS	NS	NS
WHO tumour type				
I	2	1.696	0.666	0.401
II	20	1.887	0.301	0.288
III	13	1.556	0.346	0.329
<i>p</i>		NS	NS	NS
Early vs late staging* [†]				
Early	14	1.924	0.161	0.245
Late	18	1.610	0.517	0.348
<i>p</i>		NS	0.009	NS
Neck metastasis?*				
No	7	1.995	0.219	0.257
Yes	25	1.678	0.401	0.316
<i>p</i>		NS	NS	NS
Loco-regional recurrence?‡				
No	28	1.801	0.373	0.318
Yes	4	1.444	0.302	0.167
<i>p</i>		NS	NS	NS
Survival [‡]				
Alive	23	1.848	0.267	0.281
Dead	9	1.523	0.611	0.345
<i>p</i>		NS	0.023	NS

*Staging was incomplete for three patients. [†]Early staging = stages I + II, late staging = stages III + IV. [‡]Three patients were lost to follow up. Skp2 = S-phase kinase-associated protein 2; y = years; NS = non-significant; WHO = World Health Organization

were divided into high and low levels by a cut-off point at the group median, in order to evaluate the survival period.⁹ By using the Kaplan–Meier method, patients whose tumour had a high level of cyclin E were shown to have a significantly poorer prognosis, compared with patients with low levels ($p = 0.010$, by log-rank test; Figure 2).




FIG. 2

Kaplan–Meier curve for overall patient survival by cyclin E expression, divided into high level (solid line, $n = 17$, censored = 9) and low level (dotted line, $n = 15$, censored = 14) by a cut-off point at the group median. A significant difference in cumulative overall survival was seen, comparing patients with high and low levels of cyclin E expression ($p = 0.010$, log-rank).




FIG. 3

Photomicrographs showing immunohistochemical staining for S-phase kinase-associated protein 2 (Skp2), cyclin E, and p27 protein in nasopharyngeal carcinoma tissue. (a) Strong expression of Skp2 protein; (b) weak expression of skp2 protein; (c) moderate expression of cyclin E protein; (d) positive expression of p27 protein. Note the enhanced nuclear staining of the tumour and surrounding lymphoid cells (H&E; original magnification $\times 66$).

S-phase kinase-associated protein 2, cyclin E and p27 protein were expressed locally in the cell nucleus. Although faint expression in the cytoplasm was occasionally seen, involving an unknown mechanism, we only evaluated nuclear staining (Figure 3). Analysis of the immunohistochemical results is shown in Table III. Strong staining (i.e. grades 2+ and 3+) for S-phase kinase-associated protein 2, cyclin E and p27 protein was found in 11/29 (38 per cent), 3/29 (10 per cent) and 11/29 (38 per cent) of the tissue samples, respectively. Positive (i.e. intense

or moderate) expression of the above three proteins was seen in 16/29 (55 per cent), 13/29 (45 per cent) and 17/29 (59 per cent) tissue samples, respectively. Protein expressions, as determined by immunohistochemical analysis, were not associated with clinicopathological or prognostic factors.

Discussion

To our best knowledge, the current study is the first to report the mRNA expression for cyclin E and S-phase

TABLE III
PROTEIN EXPRESSION OF SKP2, CYCLIN E AND P27 BY IMMUNOHISTOCHEMICAL ANALYSIS

Protein	Stain strength (<i>n</i>)				Expression % (<i>n</i>)		
	3+	2+	1+	0	Intense (>50%)	Mod (5–50%)	Weak (<5%)
Skp2	5	6	10	8	9	7	13
Cyclin E	2	1	14	12	11	2	16
p27	5	6	13	5	7	10	12

Skp2 = S-phase kinase-associated protein 2; mod = moderate

kinase-associated protein 2 in NPC. Our results showed a significantly elevated mRNA level for S-phase kinase-associated protein 2 but not for cyclin E, within NPC tissue, compared with normal nasopharyngeal tissue. Immunohistochemical analysis also revealed that the expression of S-phase kinase-associated protein 2 was stronger than that of cyclin E, in both the strength and positive percentage of staining. Following clinicopathological analysis, elevated levels of cyclin E mRNA were positively associated with advanced staging and poor survival of patients with NPC.

S-phase kinase-associated protein 2, an F-box protein, and S-phase kinase-associated protein one were first identified as interactors with the cyclin A cyclin-dependent kinase 2 complex.¹¹ In the cell proliferation process, S-phase kinase-associated protein 2 mediates ubiquitinylation and degradation of p27 protein through cyclin-dependent kinase 2 mediated phosphorylation on threonine 187. This process has been demonstrated both *in vitro* and *in vivo*.^{3,4} S-phase kinase-associated protein 2 mRNA is probably induced by cell adhesion to the extracellular matrix.¹ This protein plays an important role in the regulation of p27 protein within the cell cycle. S-phase kinase-associated protein 2 is also required for the ubiquitinylation of free form cyclin E.⁵ Overexpression of S-phase kinase-associated protein 2 may accelerate uncontrolled cell proliferation. This effect has been reported for many malignant tumours, such as lymphomas,^{5,6} small cell lung cancer,⁷ colorectal cancer,¹⁵ and head and neck cancer (e.g. oral cancer)¹⁶; furthermore, high levels of S-phase kinase-associated protein 2 have been found to correlate with the malignant status of the tumour. In our study, immunohistochemical analysis indicated positive expression of S-phase kinase-associated protein 2 protein in 16/29 (55 per cent) tumour samples. Studies of other human malignancies have found similar results, ranging from 30 to 55 per cent.^{17,18} High levels of S-phase kinase-associated protein 2 mRNA were also strongly associated with the NPC group, compared with normal controls ($p = 0.002$). This result may suggest that S-phase kinase-associated protein 2 acts as a proto-oncogene in the oncogenesis of NPC.

Cyclin E is a 45 kDa nuclear protein which appears in the late G1 phase of cell cycle but is then degraded after the cell enters the S phase.⁸ It is believed to be the main regulator of entry into the S phase and subsequent DNA synthesis. Although numerous studies have addressed the association between cyclin E and other cancers, specific research has not previously been conducted on cyclin E expression in NPC. In our study, we found positive expression of cyclin E protein in 13/29 (45 per cent) tumours, but strong staining for this protein (on immunohistochemical analysis) in only 3/29 (10 per cent). There was no significant difference in cyclin E mRNA levels, comparing NPC with normal tissue; however, a strong association was found between cyclin E mRNA levels and late-stage NPC ($p = 0.009$). A possible explanation for this finding is that angiogenesis or adhesive factors play the main role in the early stages of tumour oncogenesis,

whereas proliferative activity is more important in the advanced stage. The present study findings suggest that cyclin E may have a more pivotal role in cellular proliferation than angiogenesis. A similar finding was reported by Fukuse *et al.* for non-small cell lung cancer; a high cyclin E mRNA level was observed in the advanced tumour stage (stage IIIa) but not in the early stages.¹⁹ Another possible explanation is that overexpression of cyclin E leads to increased chromosome instability, which can induce development and progression of tumours, especially in the advanced stage.^{7,20} We propose that cyclin E protein expression in NPC tissues may have most impact in late-stage tumours, because of its involvement with cellular proliferation.

As regards clinicopathological analysis, Brzezinski *et al.* reported that greater cyclin E protein expression had a positive relationship with advanced tumour staging in papillary thyroid cancer.²¹ Datta *et al.* detected cyclin E positive testicular germ cell tumours at higher clinical stages of this tumour.⁸ Bani-Hani *et al.* found that cyclin E overexpression correlated with advanced stage in gastric cancer.²² In the current study, there was a significant difference in patient survival, comparing high and lower levels of cyclin E ($p = 0.010$). This result may be closely related to the correlation between cyclin E expression and late tumour stage. A correlation between high cyclin E levels and shorter survival has also been reported for breast cancer²³ and non-small cell lung cancer.^{9,20} Our findings suggest that overexpression of cyclin E may have a negative impact on the survival of patients with NPC. Therefore, cyclin E may possibly be regarded as a prognostic factor for this tumour.

- **This prospective, controlled study evaluated the expression of protein and messenger ribonucleic acid (mRNA) for cyclin E, S-phase kinase-associated protein 2 and p27 protein within nasopharyngeal carcinoma (NPC) tissue**
- **Elevated levels of S-phase kinase-associated protein 2 mRNA and reduced levels of p27 protein mRNA were found in NPC tissue, compared with normal nasopharyngeal tissue**
- **Overexpression of cyclin E mRNA had an adverse prognostic significance, correlating with advanced tumour staging and poor overall patient survival**
- **These results support the theory that S-phase kinase-associated protein 2 acted as proto-oncogenes in the oncogenesis of NPC**

An association between low p27 expression and aggressive malignancy has been observed in many cancers (in addition to NPC). Baba *et al.* found reduced expression of p27 protein in NPC.²⁴ Our previous research demonstrated that low levels of p27 protein expression correlated with high rates of early loco-regional recurrence in NPC.²⁵ In the

present study, we also found significantly reduced levels of p27 protein mRNA in NPC tissues, compared with normal controls ($p = 0.002$). These findings highlight the role of low p27 expression in NPC oncogenesis.

Conclusions

This study found elevated levels of S-phase kinase-associated protein 2 mRNA and reduced levels of p27 mRNA in NPC tissue, compared with normal nasopharyngeal tissue. High levels of cyclin E mRNA correlated with advanced staging of NPC and poor patient survival. If the results of the present report can be confirmed in larger clinical and laboratory studies, molecular genetic alterations in individual tumours may eventually be able to guide therapeutic strategies.

Acknowledgements

This study was supported by a research grant from the National Science Council of the Republic of China (92-2314-B-182A-204).

References

- Carrano AC, Pagano M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. *J Cell Biol* 2001;**153**:1381–90
- Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J *et al.* Skp2 is oncogenic and overexpressed in human cancers. *Proc Natl Acad Sci U S A* 2001;**98**:5043–8
- Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. *Curr Biol* 1999;**9**:661–4
- Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nat Cell Biol* 1999;**1**:193–9
- Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G *et al.* Role of the F-box protein Skp2 in lymphomagenesis. *Proc Natl Acad Sci U S A* 2001;**98**:2515–20
- Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D *et al.* S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. *Am J Pathol* 2002;**160**:1457–66
- Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T *et al.* A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. *Am J Pathol* 2002;**161**:207–16
- Datta MW, Renshaw AA, Dutta A, Hoffman MA, Loughlin KR. Evaluation of cyclin expression in testicular germ cell tumors: cyclin E correlates with tumor type, advanced clinical stage, and pulmonary metastasis. *Mod Pathol* 2000;**13**:667–72
- Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M *et al.* Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. *Cancer Res* 2001;**61**:647–53
- Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. *Lancet* 1997;**350**:1087–91
- Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. *Semin Oncol* 1994;**21**:382–97
- Moore C, Shen XD, Gao F, Busuttill RW, Coito AJ. Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. *Am J Pathol* 2007;**170**:567–77
- Mustafa T, Klonisch T, Hombach-Klonisch S, Kehlen A, Schmutzler C, Koehrl J *et al.* Expression of CD97 and CD55 in human medullary thyroid carcinomas. *Int J Oncol* 2004;**24**:285–94
- Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 1997;**80**:1803–4
- Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM *et al.* Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. *Cancer* 2001;**91**:1745–51
- Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. *Cancer Res* 2001;**61**:7044–7
- Kim JY, Lim SJ, Kim HJ, Shin E, Park K, Lee CM. Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. *Int J Gynecol Pathol* 2007;**26**:242–7
- Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. *Oncol Rep* 2006;**15**:765–71
- Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. *Cancer Res* 2000;**60**:242–4
- Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S *et al.* Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. *Clin Cancer Res* 2000;**6**:11–16
- Brzezinski J, Migodzinski A, Gosek A, Tazbir J, Dedecjus M. Cyclin E expression in papillary thyroid carcinoma: relation to staging. *Int J Cancer* 2004;**109**:102–5
- Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. *Clin Cancer Res* 2005;**11**:1447–53
- Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C *et al.* Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. *Oncol Rep* 2004;**12**:1143–50
- Baba Y, Tsukuda M, Mochimatsu I, Furukawa S, Kagata H, Satake K *et al.* Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. *Cancer Detect Prev* 2001;**25**:414–19
- Hwang CF, Su CY, Huang SC, Huang CC, Fang FM, Lui CC *et al.* Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. *Cancer Lett* 2003;**189**:231–6

Address for correspondence:
Dr Chung-Feng Hwang,
Department of Otolaryngology,
Chang Gung Memorial Hospital – Kaohsiung Medical Center,
Chang Gung University College of Medicine,
123 Ta-Pei Road,
Niao-Sung Hsiang,
Kaohsiung 833, Taiwan.

Fax: +886 7 7313855
E-mail: cfhwang@hotmail.com

Dr C-F Hwang takes responsibility for the integrity of the content of the paper.
Competing interests: None declared
